Corvus Pharmaceuticals shares are trading higher after Ladenburg maintained a Buy rating on the stock and raised its price target from $12 to $21.
Portfolio Pulse from Benzinga Newsdesk
Corvus Pharmaceuticals shares rose after Ladenburg reiterated a Buy rating and increased the price target from $12 to $21.
September 16, 2024 | 5:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Corvus Pharmaceuticals shares increased following Ladenburg's decision to maintain a Buy rating and raise the price target from $12 to $21.
The increase in price target from $12 to $21 by Ladenburg, along with the maintained Buy rating, is a strong positive signal for investors, likely leading to increased buying interest and a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100